MASP2 and brain inflammatory disease: To further evaluate the therapeutic potential of MASP-2 inhibition for the treatment of TBI, we tested therapeutic intervention protocols using a recombinant MASP-2 antibody that was previously shown to ameliorate ischemic stroke deficits [14] and COVID-19-induced brain inflammation [15] in mouse models, and compared it to an anti-MASP-1 antibody.